Mark Rampy
Chief Business Officer
Board of Director
Sequella Incorporated
India
Biography
Dr. Rampy has over 20 years of industry experience. Prior to Sequella, he was CEO of several start-ups (Theraly Pharmaceuticals and CohBar, Inc), VP Business Development Biologics and Specialty Products, Teva Pharmaceuticals (NYSE: TEVA), Founder and Chief Business Officer of CoGenesys, Inc. (CGS) a company spun out of Human Genome Sciences, Inc. (NASDAQ: HGSI) that was later acquired by Teva. Prior to CGS, he was with HGSI for 11 years, where he held positions of increasing responsibility in R&D and Business Development, the most senior of which was Head of Business Development. Dr. Rampy has a Ph.D. in Pharmacology from the University of Michigan and MBA from Georgetown University.
Research Interest
Molecular Biology, Pharmaceutical science, Business Management
